Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 04, 2024 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Completes Recruitment for the Synchronicity Study

ATLANTA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
June 29, 2023 08:02 ET | Source: Alumis Inc

Alumis Announces Expansion of Allosteric TYK2 Inhibitor, ESK-001, Phase 2 Program into Systemic Lupus Erythematosus (SLE) and Uveitis

– Patient dosing initiated in LUMUS, a 388 patient Phase 2b clinical trial of ESK-001 for the treatment of SLE – – Patient dosing initiated in OPTYK-1, a proof-of-concept clinical trial of ESK-001...
May 18, 2023 07:00 ET | Source: Alimera Sciences, Inc.

Alimera Acquires U.S. Commercial Rights to YUTIQ®

Expected to be immediately accretive to revenue and Adjusted EBITDA in 2023 Alimera projects at least $100 million of consolidated net revenue and over $20 million of Adjusted EBITDA* in 2024...
September 20, 2022 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Ireland

ATLANTA, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...
August 09, 2022 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Portugal

Reimbursement granted with no restrictions to the labelAlimera to begin selling later in Q3 ATLANTA, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global...
July 22, 2022 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Announces Pricing and Reimbursement of Uveitis Indication Granted for ILUVIEN® in France

ATLANTA, July 22, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
July 08, 2022 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy

ATLANTA, July 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
February 07, 2022 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Announces Launch of ILUVIEN® for Uveitis in Spain

ATLANTA, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
December 09, 2020 08:30 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Announces Launch of ILUVIEN® in the Netherlands

ATLANTA, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...
August 13, 2020 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Signs Distribution Agreement With Nordic Prime to Expand International Sales of ILUVIEN® Into Nordic Countries

ATLANTA, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...